



International p53/p63/p73 isoform workshop

**4th International p53 isoforms meeting and
9th International p63/p73 workshop**

Dubrovnik 3rd – 6th November 2019

<https://p53p63p73isoforms.irb.hr/>

Sunday 3rd November 2019

Registration from 2 pm

15:00 – 15:10 Opening and introduction

Neda SLADE, *Ruđer Bošković Institute, Zagreb, Croatia*

Physiological roles, molecular and cellular mechanisms

Chairs: Bjørn Gjersten and Yari Ciribilli

15:10 – 15:50

Keynote Lecture sponsored by Cancers

Jean-Christophe BOURDON, *University of Dundee, UK*

Towards a p53 code?

15:50 – 16:15

Cecilia Blair LEVANDOWSKI, *University of Colorado Boulder CO, USA*

How does $\Delta 40p53$ alter WTp53 function?

16:15 – 16:40

Kelly AVERY-KIEJDA, *University of Newcastle, Australia*

The role of $\Delta 40p53$ in the response to DNA damaging therapies in breast cancer cells

16:40 – 17:05

Neda SLADE, *Ruđer Bošković Institute, Zagreb, Croatia*

Functional interplay between p53 and p53/p73 isoforms in human melanoma

Coffee break

17:25 – 17:40

Martin FISCHER, *Leibniz Institute on Aging – Fritz Lipmann Institute, Germany*

Dissecting the binding landscape and gene regulatory network of p63 and p53

17:40 – 17:55

Morgan A. SAMMONS, *State University of New York at Albany, USA*

Determinants of cis-regulatory activity for the p53 family of transcription factors

17:50 – 18:15

Alexander ZAIKA, *University of Miami Health System, USA*

Formation of protein adducts causes inactivation of p53 protein and its aggregation

18:15 – 18:40

Pierre ROUX, *CRBM CNRS, France*

$\Delta 133p53\beta$ isoform invasive activity: mechanism of action and regulation

18:40 – 18:55

Nicole HEINZL, *Medical University of Vienna, Austria*

The prognostic impact of p53 aggregates in high-grade serous ovarian cancer

18:55 – 19:20

Alea MILLS, *Cold Spring Harbor Laboratories, USA*

p53: dictator of epigenetic vulnerabilities in human glioma

19:20 – 21:30 Welcome dinner

Monday 4th November 2019

Ageing, stem cells and cell reprogramming. Multi-cellular organisation of tissue and organs

Chairs: Alea Mills, Jeffrey W. Pollard and Thomas F. Meyer

08:15 – 09:00

Keynote lecture

Curtis HARRIS, *NCI NIH, USA*

Ageing and cancer: p53 isoforms

09:00 – 09:25

Margareta WILHELM, *Karolinska Institute, Stockholm, Sweden*

p53 controls genomic stability and temporal differentiation of human neural stem cells and affects neural organisation in human brain organoids

09:25 – 09:50

Juan J. TENA, Andalusian Center for Development Biology CABD, Seville, Spain
Roles of p63 during ectoderm specification

09:50 – 10:15

Ting ZHAO, University of Zhejiang, China
p53 isoform delta113p53 promotes zebrafish heart regeneration via maintaining ROS homeostasis

10:15 – 10:40

Jo Huiqing ZHOU, Radboud Institute of Molecular Life Sciences, Nijmegen, The Netherlands
Transcription factor p63: guardian of the epithelial cell fate?

Coffee break

11:00 – 11:25

Maria C. MARIN, Universidad de León, Spain
p73 an architect of epithelial tissue

11:25 – 11:40

Yan SUN, Cancer Research Centre of Lyon, UMR INSERM 1052 – CNRS 5286, Lyon, France
Regulation of netrin-1 by p53 isoforms

11:40 – 11:55

Jin ZHANG, University of California, Davis, USA
Mutant p53 antagonizes p63/p73-mediated tumor suppression via Notch1

11:55 - 12:20

Caterina MISSERO, University of Naples Federico II, Naples, Italy
Overlapping transcriptional programs downstream of p63 and p73 promote cutaneous squamous cell carcinoma

12:20 – 12:45

Flash Poster presentations (2 min per poster)

12:50 – 13:30 Lunch

13:30 – 13:45 Posters

Maintenance and restoration of tissue integrity and function in response to infection, and oxidative stress. Role in the coordination of the immune response

Chairs: Jean-Christophe Bourdon and Curtis Harris

14:15 – 15:00

Keynote Lecture sponsored by Cancers
Jeffrey W. POLLARD, University of Edinburgh, UK & Albert Einstein College of Medicine, USA
Macrophage diversity plays an essential role in development, repair and disease

15:00 – 15:25

Max WELLENSTEIN, Netherlands Cancer Institute, The Netherlands
p53 status dictates pro-metastatic systemic inflammation in breast cancer

15:25 – 15:40

Marina KAZANTSEVA, University of Otago, Dunedin, New Zealand
 $\Delta 133p53\beta$ isoform regulates unique gene sets involved in immunosuppression, cell growth and cell migration

15:40 – 15:55

Hakim ECHCHANNAOUI, Johannes Gutenberg University Mainz, Germany
Targeting $\Delta 133p53\alpha$ as a novel T cell enhancer factor to improve cellular-based immunotherapy for cancer

15:55 – 16:10

Sunali MEHTA, University of Otago, Dunedin, New Zealand
Modulation of Dendritic Cell function by $\Delta 133p53$ isoforms

Coffee break

16:30 – 16:55

Thomas F. MEYER, Max Planck Institute for Infection Biology, Germany
Role of p53 in the interplay between host cell and pathogens

16:55 – 17:10

Yann BRETON Centre de recherche du CHU de Québec-Université Laval, Canada
An antiviral role for p53 against HIV-1 in macrophages and the implication of the p53 isoforms

17:10 – 17:25

Lucie CAPPUCIO, UMR754, Lyon, France and Institut Pasteur Shanghai, China
Opposite effect of p53 on chikungunya virus replication in mammal and insect

17:25 – 17:40

Anaïs BLANCHET, INSERM UMR_S1113, University of Strasbourg, France
Identification of novel partners/regulators of p73 proteins in gastric cancer

17:40 – 18:05

Christian GAIDON, INSERM, University of Strasbourg, France
Role of the p53 family in muscle atrophy associated with ALS and cancer

18:05 – 18:30

Antony BRAITHWAITE, University of Otago, New Zealand
Elevated levels of $\Delta 133p53\beta$ isoform are found in Rheumatoid Arthritis patients with hyperproliferative synovium and exaggerated immune cell infiltration

Tuesday 5th November 2019

Mutation and interplay

Chairs: Antony Braithwaite and Neda Slade

8:15 – 8:40

Elsa FLORES, Moffitt Cancer Center, Tampa, Florida, USA
Pan-cancer analysis reveals alternate mechanisms for AKT activation through TAp63 regulated oncogenic lncRNAs (TROLLs)

8:40 – 9:05

Volker DÖTSCH, Goethe University, Frankfurt, Germany
Mechanism of inhibition and activation of TAp63 α in oocytes

9:05 – 9:20

Sebastien JORUIZ, NCI NIH, USA
Functional analysis of wild-type and mutant p53 isoforms

9:20 – 9:45

Tom VAN WEZEL, Leiden University Medical Centre, The Netherlands
Germline variant affecting p53 β isoforms predisposes to various familial cancers

9:45 – 10:10

Daniele BERGAMASCHI, Queen Mary London University, UK
Impact of p63 upregulation on MAPK inhibitors resistance in melanoma

10:10 – 10:35

Luisa GUERRINI, University of Milano, Italy
Thalidomide teratogenicity uncovered- the central role of p63 and CRBN

Coffee break

11:00 – 11:25

Yari CIRIBILLI, CIBIO-Centre for Integrative Biology, University of Trento, Italy
Impact of p53 isoforms over-expression in lung cancer

11:25 – 11:50

James MANFREDI, Icahn School of Medicine at Mount Sinai, USA.
Tissue-specific tumor suppressor functions of p53 in vivo

11:50 – 12:15

Claude CARON DE FROMENTEL, Cancer Research Center of Lyon, France
DeltaNp73 expression impacts on stem-like cell properties of acute myeloid leukemia and hepatocellular carcinoma tumors

12:15 – 12:45

Flash Poster presentations (2 min per poster)

12:45 – 13:30 Lunch

13:30 – 14:15 Posters

Regulation, splicing and treatment

14:15 – 14:40

Michael KASTAN, Duke Cancer Institute, Durham, USA
DNA damage-induced alternative splicing of p53

14:40 – 14:55

Annette LASHAM, University of Otago, New Zealand
Quantitation and analysis of alternatively-spliced TP53 RNAs in a NZ breast cancer cohort, using a novel multiplex long amplicon digital PCR method

14:55 – 15:10

Jayanthi P. GUDIKOTE, *University of Texas M.D. Anderson Cancer Center, Houston, USA*
Targeting nonsense-mediated decay and mRNA splicing to activate p53 pathway in p53 mutant and non-mutant cancer cells

15:10 – 15:25

William TAYLOR, *Univ Rennes, CNRS, IGDR, UMR 6290, France*
The RNA Binding protein PTBP1 controls the alternative splicing of the C-terminal Exons of TP63 in HNSCC.

15:25 – 15:50

Xinbin CHEN, *Comparative Oncology Laboratory, University of California, USA*
Targeting the p53-Rbm38 loop for tumor suppression

15:50 – 16:15

Sue HAUPT, *Peter MacCallum Cancer Centre, Melbourne, Australia*
In the loop with p53: isoforms and cancer

18:30 Sightseeing Dubrovnik

19:30 Gala dinner

Wednesday 6th November 2019

Biomarkers and targeting isoforms

Chairs: Claude Caron de Fromentel and Pierre Roux

08:15 – 09:00

The EMBO Keynote Lecture
Varda ROTTER, *Weizmann Institute of Science, Israel*
Development of a mutant p53-dependent novel cancer therapy

09:00 – 09:25

Bjørn GJERTSEN, *University of Bergen, Norway*
The landscape of p53 isoforms in normal blood cells and acute leukemia

09:25 – 09:40

GEMMA DOMÍNGUEZ, *CSIC-UAM, IdiPaz, Madrid, Spain*
Exosomal ΔNp73, TAp73 and Δ133p53 isoforms as early diagnosis markers in colorectal cancer

09:40 – 10:05

Klas WIMAN, *Karolinska Institute, Stockholm, Sweden*
Rescue of missense and nonsense mutant p53: from bench to bedside

10:05 – 10:30

Joanna ZAWACKA-PANKAU, *Stockholm, Sweden*
Drug repositioning to target p73 for improved cancer therapy

Coffee break

10:50 – 11:15

Ygal HAUPT, *Peter MacCallum Cancer Centre, Melbourne, Australia*
Targeting MDM proteins in wt and mutant p53 cancers

11:15 – 11:30

Giovanni MINERVINI, *University of Padova, Dept. Biomedical Sciences, Italy*
The E3 ubiquitin-protein ligase Mdm2 is a novel interactor of the von Hippel-Lindau tumor suppressor

11:30 – 11:45

Thomas G HOFMANN, *Institute of Toxicology, University of Mainz, Germany*
DAZAP2 acts as phosphorylation-dependent specifier of the p53 response controlling cancer cell chemosensitivity

11:45 – 12:10

Ivano AMELIO, *University of Cambridge, UK*
p53 family isoforms and mutations in response to microenvironmental stressors

12:10 – 12:35

Simon MCDADE, *Queen's University Belfast, UK*
Functional genomics identifies a novel p53 induced ligand-independent TRAIL-R2/FLIP complex as a novel therapeutic vulnerability

12:35 – 13:00

Jean-Christophe BOURDON, *University of Dundee, School of Medicine, UK*
Conclusion